


FOSUN PHARMA
复星医药

2022



1

2

3

4

5

6



439.52 ↑

+12.66% YoY

139.38 ↑

+2.49% YoY

30% ↑

25%

31.7%

38.73 ↑

+18.17% YoY

42.18 ↑

+7.10% YoY

MSCI-ESG

BBB

A

A



® **PD-1**
MSI-H sqNSCLC ES-SCLC SCLC
FDA EC
MAA EMA *

®
2022
® **CAR-T**
10

13

III
mRNA

®

RT002

III

SCLC

Tenapanor NHE3

*



®
Parsabiv®

Organon Eurofarma
Abbott



Syneos Health
PD-1

Gland
Pharma
Cenexi
CDMO

Sisram

66%



GT1-GT6

CMC

SAB

Scientific Advisor
Board

5

®

2022

674

	2021	2022	YoY
	390.11	439.52	12.7%
	47.29	37.31	-21.1%
	32.77	38.73	18.2%
	39.38	42.18	7.1%
	49.78	58.85	18.2%
	38.37	43.02	12.1%
	1.85	1.43	-22.7%
()	30%	30%	-

	2021	2022
	48.1%	47.3%
	23.3%	20.9%
	8.3%	8.7%
	9.8%	9.8%
	1.2%	1.5%
	24.8%	26.4%


	2021	2022
	103.17	162.41
	391.96	445.82
	1.04	1.06
	0.85	0.85
	48.2%	49.5%

BNTX -1.42 15.93 , BNTX
 -10 37.31
 21.10%

1
 2) 2.96
 3
 1
 2
 3
 2022 7
 44.8
 A
 1
 2
 A



-





1
2
3
4

BNTX

2022

2021







/ADC RNA



ADC"



RNAi

mRNA



" CAR-



&

02



CNS

01



03



50%

FIC+BIC

[Dark blue header bar]

[Dark blue header bar]

MSI-H ® PD-1

® CAR-T

® CD20


® HER2


®

®

®







FES Fosun Ecosystem/Entrepreneurship System

SRM

INNOX

2022 FES



OBM

OTC


6,000

2022

20.87%

2.46

1/2










&

&BD&

:



&



, &BD



MSCI-ESG

A

2022

BBB
2021

BB
2020



Environment

EHS	EHS	EHS
2021-2026	2022	2022
337,806	115.36	3.2%







Social

A



-



RNA

/ADC

55.22 26%¹
+39.44% YoY


TNF-
PD-1 ® HER2 ®
 ® ®
 ® ®

YoY **50.97** +13.62%
85%

16.54%
11.53% 35.52

30%

260 2022
249
16 PCT 17
48





SCLC

PD-1

3.4

2022

9

®



ES-SCLC

III

(OS)

OS

15.4

10.9

24

43.1%

7.9%



PD-1

MSI-H

SCLC FDA EC

JAMA

Nature Medicine

British Journal of Cancer

nature
medicine

JAMA
The Journal of the American Medical Association

BJC
Journal of Cancer
British




27

110

30%

400

DTP



2022

10	5		mRNA	
			® HER2	
			® CD20	
			®	
5	10	3	®	
			®	
3	5	8	® PD-1	
			®	
			®	VERO
				8
1	3	31	® TNF-	
			®	
			®	
			®	31






2022



2022

2022




Alma Ted




LMNT one



CBD+Professional Skincare Solution





2016
2017

Intuitive Surgical

200 800

Xi

1,700 4,000

31.2



2022

55
300

10

2000

FDA

7,544

2022 12 31
55,000
1,000

Ion


2019 Ion
FDA

2021 10 Ion




Ion



2022









JCI

"

6,333 *


JVF

		JCI国际认证医院 Organization Accredited by Joint Commission International	2022	21.45	1,750 1.11
86.47%					
	深圳恒生医院 SHENZHEN HENGSHENG HOSPITAL		2017	11 60%	600 9.09
	浙江大学医学院附属第一医院 ZHEJIANG UNIVERSITY OF MEDICINE FIRST AFFILIATED HOSPITAL		2022	1	800 70%



-

[Placeholder text box]



[Placeholder text box]



()

521,051

6.0% YoY

552,148

2021

2022

()

7,759

10.0% YoY

8,526

2021

2022

()

1,948

8.5% YoY

2,114

2021

2022

		4,066	4.27%
"	"		
	1,209	11.77%	
	330	13.49%	



1/2



2/2

		/		IND	1	2	3	NDA
FS-1502		HER2	HER2					
			HER2					
FS-1502+		HER2+PD-1	HER2					
HLX14	¹ 	RANKL						
HLX26		LAG-3						
HLX35 ²		EGFR× 4-1BB		2022 1 NMPA	2022 6			
HLX301		PD-L1× TIGIT		2022 2	2022 3 NMPA		7	
HLX15		CD38						
HLX13		CTLA-4						
		EPO						
		INSR						
	50R	INSR						
		GLP-1						
RT002			GL					
			CD	2022 1				

- 1 Organon
- 2 Binacea

3

2023 2 28

1/2

	/		IND	1	2	3	NDA
FCN-437c	CDK4/6	(1L)	2022	1	NMPA	III	I
		(2L)	2022	1		III	
SAF-189	ALK		2022	1	NMPA	III	I
	ROS1						
HLX-208	BRAF V600E	LCH ECD	2022	1	NMPA	Ib/II	
FCN-159	MEK	I					
			2022	5	NMPA		
		2022	5	NMPA			
YP01001	VEGFR						
FCN-338	BCL-2						
		B					
FH-2001	FGFR/PD-L1						

2/2

		/			IND	1	2	3	NDA
		TPO-R	ITP						
	Tenapanor	NHE 3	(ESRD-HD)	2022 12 NDA NMPA					
		-							
	Tenapanor	NHE 3	(IBS-C)		I				
	FCN-342	URAT1							
	Molnupiravir	RNA							
	Paxlovid	3CL							
	BNT162b2	-						EUA	
	PA-824	-	/ MDR-TB	XDR-TB	Pretomanid*				
	Opicapone	COMT			Ongentys*				
	Fortacin	-			*				
	ET-26	-			2022 7	II			

2023 2 28

LOGO

Fosun Pharma, the Representer or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representer or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun Pharma, are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com